{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T20:00:39Z","timestamp":1780171239642,"version":"3.54.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70116815"],"award-info":[{"award-number":["70116815"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70116815"],"award-info":[{"award-number":["70116815"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["324392634 - TRR 221 (B02)"],"award-info":[{"award-number":["324392634 - TRR 221 (B02)"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WA 1025\/31-3"],"award-info":[{"award-number":["WA 1025\/31-3"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The receptors of the tumor necrosis factor (TNF) receptor superfamily (TNFRSF) are of overwhelming scientific and clinical relevance and stand at the center of intensive basic and translational research efforts. TNFRSF receptors (TNFRs) are engaged by membrane-bound ligands of the TNF superfamily (TNFSF) and, in some cases, by soluble ligand molecules released from the membrane-bound TNFSF ligand (TNFL) molecules. The development of recombinant TNFL-based TNFR agonists for research and especially therapeutic purposes is highly \u201cindividualized\u201d, as ligand type-specific hurdles must be overcome in terms of stability, manufacturability, TNFR-specificity and need for oligomerization. TNFR-specific antibodies can also show agonistic activity, but this agonism typically requires Fc\u03b3R-binding, resulting in a reciprocal conditional bispecific Fc\u03b3R\/TNFR agonism not useful for the study or exploitation of pure TNFR agonism. Some antibodies trigger intrinsic TNFR agonism independent from Fc\u03b3R-binding, but the rational development of such antibodies is poorly predictable and furthermore challenging due to isotype- and epitope-requirements and poor specific activity when benchmarked with Fc\u03b3R-bound anti-TNFR antibodies.<\/jats:p>\n                  <jats:p>Using a series of nanobodies (or single-domain antibodies (sdAbs) or variable heavy domain of heavy chains (VHHs)) specific for the TNFRSF members 41BB, BCMA, CD40, CD95, TRAILR2\/DR5, GITR, OX40, TNFR1 and TNFR2, we show here that genetic fusion of single-chain encoded triplets of these nanobodies with oligomerizing protein scaffolds regularly results in potent hexa-, nona- and dodecavalent agonists inducing TNFR signaling with EC50-values in the sub-nanomolar range. The oligovalent nanobody formats described exhibit superior CMC properties and enable the simple generation of highly active TNFR agonists from virtually any TNFR-specific nanobody.<\/jats:p>","DOI":"10.1038\/s41419-026-08911-x","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T17:04:10Z","timestamp":1780160650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A simple and broadly applicable nanobody-based approach to generate potent TNFR agonists"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6369-4973","authenticated-orcid":false,"given":"Isabell","family":"Lang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Zaitseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Gl\u00f6ckler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalia","family":"Sheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayan","family":"Mouhandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weisenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Stepanzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3165-2648","authenticated-orcid":false,"given":"Andreas","family":"Beilhack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Crauel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Kilisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa-Marie","family":"Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansj\u00f6rg","family":"G\u00f6tzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2005-3949","authenticated-orcid":false,"given":"Harald","family":"Wajant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"8911_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0968-0004(01)01995-8","volume":"27","author":"JL Bodmer","year":"2002","unstructured":"Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci. 2002;27:19\u201326.","journal-title":"Trends Biochem Sci"},{"key":"8911_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","volume":"104","author":"RM Locksley","year":"2001","unstructured":"Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001;104:487\u2013501.","journal-title":"Cell"},{"key":"8911_CR3","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/cdd.2015.109","volume":"22","author":"H Wajant","year":"2015","unstructured":"Wajant H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ. 2015;22:1727\u201341.","journal-title":"Cell Death Differ"},{"key":"8911_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1147467","volume":"14","author":"O Dadas","year":"2023","unstructured":"Dadas O, Ertay A, Cragg MS. Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives. Front Immunol. 2023;14:1147467.","journal-title":"Front Immunol"},{"key":"8911_CR5","doi-asserted-by":"crossref","unstructured":"Kucka K, Wajant H. Receptor oligomerization and its relevance for signaling by receptors of the tumor necrosis factor receptor superfamily. Front Cell Dev Biol. 2020; 8: 615141.","DOI":"10.3389\/fcell.2020.615141"},{"key":"8911_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119:651\u201365.","journal-title":"Blood"},{"key":"8911_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/physrev.00045.2017","volume":"99","author":"C Dostert","year":"2019","unstructured":"Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev. 2019;99:115\u201360.","journal-title":"Physiol Rev"},{"key":"8911_CR8","doi-asserted-by":"crossref","unstructured":"Veerasubramanian PK, Wynn TA, Quan J, Karlsson FJ. Targeting TNF\/TNFR superfamilies in immune-mediated inflammatory diseases. J Exp Med. 2024;221:e20240806.","DOI":"10.1084\/jem.20240806"},{"key":"8911_CR9","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1038\/sj.cdd.4402213","volume":"14","author":"D Berg","year":"2007","unstructured":"Berg D, Lehne M, M\u00fcller N, Siegmund D, M\u00fcnkel S, Sebald W, et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ. 2007;14:2021\u201334.","journal-title":"Cell Death Differ"},{"key":"8911_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.45","volume":"1","author":"B Schneider","year":"2010","unstructured":"Schneider B, M\u00fcnkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H, et al. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis. 2010;1:e68.","journal-title":"Cell Death Dis"},{"key":"8911_CR11","doi-asserted-by":"publisher","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","volume":"16","author":"H Walczak","year":"1997","unstructured":"Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. Embo J. 1997;16:5386\u201397.","journal-title":"Embo J"},{"key":"8911_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1236332","volume":"14","author":"G Fromm","year":"2023","unstructured":"Fromm G, de Silva S, Schreiber TH. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. Front Immunol. 2023;14:1236332.","journal-title":"Front Immunol"},{"key":"8911_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.chembiol.2024.03.010","volume":"31","author":"HS Jhajj","year":"2024","unstructured":"Jhajj HS, Schardt JS, Khalasawi N, Yao EL, Lwo TS, Kwon NY, et al. Facile generation of biepitopic antibodies with intrinsic agonism for activating tumor necrosis factor receptors. Cell Chem Biol. 2024;31:944\u2013954.e945.","journal-title":"Cell Chem Biol"},{"key":"8911_CR14","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1189\/jlb.72.5.847","volume":"72","author":"E Hoffmann","year":"2002","unstructured":"Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002;72:847\u201355.","journal-title":"J Leukoc Biol"},{"key":"8911_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/2326-6066.CIR-20-0138","volume":"9","author":"I de Weerdt","year":"2021","unstructured":"de Weerdt I, Lameris R, Scheffer GL, Vree J, de Boer R, Stam AG, et al. A bispecific antibody antagonizes prosurvival CD40 signaling and promotes V\u03b39V\u03b42 T cell-mediated antitumor responses in human B-cell malignancies. Cancer Immunol Res. 2021;9:50\u201361.","journal-title":"Cancer Immunol Res"},{"key":"8911_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2024.2302246","volume":"15","author":"N Hesen","year":"2024","unstructured":"Hesen N, Anany M, Freidel A, Baker M, Siegmund D, Zaitseva O, et al. Genetically engineered IgG1 and nanobody oligomers acquire strong intrinsic CD40 agonism. Bioengineered. 2024;15:2302246.","journal-title":"Bioengineered"},{"key":"8911_CR17","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591\u2013604.","journal-title":"J Biol Chem"},{"key":"8911_CR18","doi-asserted-by":"publisher","first-page":"10602","DOI":"10.1074\/jbc.273.17.10602","volume":"273","author":"RA Kammerer","year":"1998","unstructured":"Kammerer RA, Schulthess T, Landwehr R, Lustig A, Fischer D, Engel J. Tenascin-C hexabrachion assembly is a sequential two-step process initiated by coiled-coil alpha-helices. J Biol Chem. 1998;273:10602\u20138.","journal-title":"J Biol Chem"},{"key":"8911_CR19","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1126\/science.8248779","volume":"262","author":"PB Harbury","year":"1993","unstructured":"Harbury PB, Zhang T, Kim PS, Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science. 1993;262:1401\u20137.","journal-title":"Science"},{"key":"8911_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-021-00332-6","volume":"9","author":"Y Asaadi","year":"2021","unstructured":"Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F. A comprehensive comparison between camelid nanobodies and single-chain variable fragments. Biomark Res. 2021;9:87.","journal-title":"Biomark Res"},{"key":"8911_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","volume":"83","author":"M Grell","year":"1995","unstructured":"Grell M, Douni E, Wajant H, L\u00f6hden M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 1995;83:793\u2013802.","journal-title":"Cell"},{"key":"8911_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03633-8","volume":"12","author":"K Kucka","year":"2021","unstructured":"Kucka K, Lang I, Zhang T, Siegmund D, Medler J, Wajant H. Membrane lymphotoxin-\u03b1(2)\u03b2 is a novel tumor necrosis factor (TNF) receptor 2 (TNFR2) agonist. Cell Death Dis. 2021;12:360.","journal-title":"Cell Death Dis"},{"key":"8911_CR23","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1128\/MCB.23.4.1428-1440.2003","volume":"23","author":"N Holler","year":"2003","unstructured":"Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23:1428\u201340.","journal-title":"Mol Cell Biol"},{"key":"8911_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2016.12.012","volume":"168","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-\u03baB: a blossoming of relevance to human pathobiology. Cell. 2017;168:37\u201357.","journal-title":"Cell"},{"key":"8911_CR25","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fimmu.2014.00063","volume":"5","author":"JA Carmona Arana","year":"2014","unstructured":"Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H. TNF receptor-associated factor 1 is a major target of soluble TWEAK. Front Immunol. 2014;5:63.","journal-title":"Front Immunol"},{"key":"8911_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1396-5","volume":"10","author":"S F\u00fcllsack","year":"2019","unstructured":"F\u00fcllsack S, Rosenthal A, Wajant H, Siegmund D. Redundant and receptor-specific activities of TRADD, RIPK1 and FADD in death receptor signaling. Cell Death Dis. 2019;10:122.","journal-title":"Cell Death Dis"},{"key":"8911_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000289201","volume":"11","author":"X Chen","year":"2010","unstructured":"Chen X, Oppenheim JJ. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Curr Dir Autoimmun. 2010;11:119\u201334.","journal-title":"Curr Dir Autoimmun"},{"key":"8911_CR28","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/eji.200324804","volume":"34","author":"S Ronchetti","year":"2004","unstructured":"Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. Eur J Immunol. 2004;34:613\u201322.","journal-title":"Eur J Immunol"},{"key":"8911_CR29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/eji.201948393","volume":"50","author":"M Lubrano di Ricco","year":"2020","unstructured":"Lubrano di Ricco M, Ronin E, Collares D, Divoux J, Gr\u00e9goire S, Wajant H, et al. Tumor necrosis factor receptor family costimulation increases regulatory T-cell activation and function via NF-\u03baB. Eur J Immunol. 2020;50:972\u201385.","journal-title":"Eur J Immunol"},{"key":"8911_CR30","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1002\/cncr.29991","volume":"122","author":"J Jakob","year":"2016","unstructured":"Jakob J, Hohenberger P. Role of isolated limb perfusion with recombinant human tumor necrosis factor \u03b1 and melphalan in locally advanced extremity soft tissue sarcoma. Cancer. 2016;122:2624\u201332.","journal-title":"Cancer"},{"key":"8911_CR31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.vaccine.2011.11.088","volume":"30","author":"SK Kanagavelu","year":"2012","unstructured":"Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, et al. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to an HIV-1 Gag DNA vaccine. Vaccine. 2012;30:691\u2013702.","journal-title":"Vaccine"},{"key":"8911_CR32","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1111\/j.1742-4658.2008.06382.x","volume":"275","author":"N M\u00fcller","year":"2008","unstructured":"M\u00fcller N, Wyzgol A, M\u00fcnkel S, Pfizenmaier K, Wajant H. Activity of soluble OX40 ligand is enhanced by oligomerization and cell surface immobilization. FEBS J. 2008;275:2296\u2013304.","journal-title":"FEBS J"},{"key":"8911_CR33","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1128\/JVI.80.4.1762-1772.2006","volume":"80","author":"GW Stone","year":"2006","unstructured":"Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu XF, et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol. 2006;80:1762\u201372.","journal-title":"J Virol"},{"key":"8911_CR34","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.4049\/jimmunol.0802597","volume":"183","author":"A Wyzgol","year":"2009","unstructured":"Wyzgol A, M\u00fcller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009;183:1851\u201361.","journal-title":"J Immunol"},{"key":"8911_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06993-4","volume":"7","author":"R Fischer","year":"2017","unstructured":"Fischer R, Marsal J, Gutt\u00e0 C, Eisler SA, Peters N, Bethea JR, et al. Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Sci Rep. 2017;7:6607.","journal-title":"Sci Rep"},{"key":"8911_CR36","doi-asserted-by":"publisher","first-page":"7394","DOI":"10.1074\/jbc.M109.037341","volume":"285","author":"H Rauert","year":"2010","unstructured":"Rauert H, Wicovsky A, M\u00fcller N, Siegmund D, Spindler V, Waschke J, et al. Membrane tumor necrosis factor (TNF) induces p100 processing via TNF receptor-2 (TNFR2). J Biol Chem. 2010;285:7394\u2013404.","journal-title":"J Biol Chem"},{"key":"8911_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24450-8","volume":"8","author":"M Siegemund","year":"2018","unstructured":"Siegemund M, Schneider F, Hutt M, Seifert O, M\u00fcller I, Kulms D, et al. IgG-single-chain TRAIL fusion proteins for tumour therapy. Sci Rep. 2018;8:7808.","journal-title":"Sci Rep"},{"key":"8911_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.888274","volume":"13","author":"JG Vargas","year":"2022","unstructured":"Vargas JG, Wagner J, Shaikh H, Lang I, Medler J, Anany M, et al. A TNFR2-specific TNF fusion protein with improved in vivo activity. Front Immunol. 2022;13:888274.","journal-title":"Front Immunol"},{"key":"8911_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/CJI.0000000000000246","volume":"41","author":"C Merz","year":"2018","unstructured":"Merz C, Sykora J, Marschall V, Richards DM, Heinonen K, Redondo M\u00fcller M, et al. The hexavalent CD40 agonist HERA-CD40L induces T-cell-mediated antitumor immune response through activation of antigen-presenting cells. J Immunother. 2018;41:385\u201398.","journal-title":"J Immunother"},{"key":"8911_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70517","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Qian X, Wang Y, Yu C, Feng L, Zheng X, et al. Turn TRAIL into better anticancer therapeutic through trail fusion proteins. Cancer Med. 2025;14:e70517.","journal-title":"Cancer Med"},{"key":"8911_CR41","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.4049\/jimmunol.149.10.3166","volume":"149","author":"J Dhein","year":"1992","unstructured":"Dhein J, Daniel PT, Trauth BC, Oehm A, M\u00f6ller P, Krammer PH. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol. 1992;149:3166\u201373.","journal-title":"J Immunol"},{"key":"8911_CR42","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.7150\/jca.19918","volume":"8","author":"L Guo","year":"2017","unstructured":"Guo L, Sun X, Hao Z, Huang J, Han X, You Y, et al. Identification of novel epitopes with agonistic activity for the development of tumor immunotherapy targeting TRAIL-R1. J Cancer. 2017;8:2542\u201353.","journal-title":"J Cancer"},{"key":"8911_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abm3723","volume":"7","author":"CM Orr","year":"2022","unstructured":"Orr CM, Fisher H, Yu X, Chan CH, Gao Y, Duriez PJ, et al. Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Sci Immunol. 2022;7:eabm3723.","journal-title":"Sci Immunol"},{"key":"8911_CR44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2020.04.013","volume":"37","author":"X Yu","year":"2020","unstructured":"Yu X, Chan HTC, Fisher H, Penfold CA, Kim J, Inzhelevskaya T, et al. Isotype switching converts anti-CD40 antagonism to agonism to elicit potent antitumor activity. Cancer Cell. 2020;37:850\u2013.e857.","journal-title":"Cancer Cell"},{"key":"8911_CR45","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ccell.2018.02.009","volume":"33","author":"X Yu","year":"2018","unstructured":"Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, et al. Complex Interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. Cancer Cell. 2018;33:664\u2013.e664.","journal-title":"Cancer Cell"},{"key":"8911_CR46","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s42003-021-02309-5","volume":"4","author":"X Yu","year":"2021","unstructured":"Yu X, James S, Felce JH, Kellermayer B, Johnston DA, Chan HTC, et al. TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity. Commun Biol. 2021;4:772.","journal-title":"Commun Biol"},{"key":"8911_CR47","doi-asserted-by":"crossref","unstructured":"Griffiths J, Hussain K, Smith HL, Sanders T, Cox KL, Semmrich M, et al. Domain binding and isotype dictate the activity of anti-human OX40 antibodies. J Immunother Cancer 2020;8:e001557.","DOI":"10.1136\/jitc-2020-001557"},{"key":"8911_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s42003-022-03182-6","volume":"5","author":"F Heckel","year":"2022","unstructured":"Heckel F, Turaj AH, Fisher H, Chan HTC, Marshall MJE, Dadas O, et al. Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Commun Biol. 2022;5:229.","journal-title":"Commun Biol"},{"key":"8911_CR49","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1016\/j.celrep.2019.05.027","volume":"27","author":"P Zhang","year":"2019","unstructured":"Zhang P, Tu GH, Wei J, Santiago P, Larrabee LR, Liao-Chan S, et al. Ligand-blocking and membrane-proximal domain targeting anti-OX40 antibodies mediate potent T cell-stimulatory and anti-tumor activity. Cell Rep. 2019;27:3117\u20133123.e3115.","journal-title":"Cell Rep"},{"key":"8911_CR50","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1038\/s41418-023-01229-7","volume":"30","author":"T Mondal","year":"2023","unstructured":"Mondal T, Gaur H, Wamba BEN, Michalak AG, Stout C, Watson MR, et al. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer. Cell Death Differ. 2023;30:2408\u201331.","journal-title":"Cell Death Differ"},{"key":"8911_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109953","volume":"37","author":"G Shivange","year":"2021","unstructured":"Shivange G, Mondal T, Lyerly E, Bhatnagar S, Landen CN, Reddy S, et al. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. Cell Rep. 2021;37:109953.","journal-title":"Cell Rep"},{"key":"8911_CR52","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/febs.13968","volume":"284","author":"D Siegmund","year":"2017","unstructured":"Siegmund D, Lang I, Wajant H. Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2. Febs j. 2017;284:1131\u201359.","journal-title":"Febs j"},{"key":"8911_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.404","volume":"5","author":"I Karl","year":"2014","unstructured":"Karl I, Jossberger-Werner M, Schmidt N, Horn S, Goebeler M, Leverkus M, et al. TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis. Cell Death Dis. 2014;5:e1444.","journal-title":"Cell Death Dis"},{"key":"8911_CR54","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.1074\/jbc.M115.683946","volume":"291","author":"I Lang","year":"2016","unstructured":"Lang I, F\u00fcllsack S, Wyzgol A, Fick A, Trebing J, Arana JA, et al. Binding studies of the TNF receptor superfamily (TNFRSF) receptors on intact cells. J Biol Chem. 2016;291:5022\u201337.","journal-title":"J Biol Chem"},{"key":"8911_CR55","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/19420862.2016.1274844","volume":"9","author":"J Kums","year":"2017","unstructured":"Kums J, Nelke J, R\u00fcth B, Sch\u00e4fer V, Siegmund D, Wajant H. Quantitative analysis of cell surface antigen-antibody interaction using Gaussia princeps luciferase antibody fusion proteins. MAbs. 2017;9:506\u201320.","journal-title":"MAbs"},{"key":"8911_CR56","doi-asserted-by":"crossref","unstructured":"Zhai T, Wang C, Xu Y, Huang W, Yuan Z, Wang T, et al. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer. J Immunother Cancer 2021;9:e002131.","DOI":"10.1136\/jitc-2020-002131"},{"key":"8911_CR57","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1074\/jbc.M114.617787","volume":"290","author":"S Steeland","year":"2015","unstructured":"Steeland S, Puim\u00e8ge L, Vandenbroucke RE, Van Hauwermeiren F, Haustraete J, Devoogdt N, et al. Generation and characterization of small single-domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem. 2015;290:4022\u201337.","journal-title":"J Biol Chem"},{"key":"8911_CR58","doi-asserted-by":"publisher","first-page":"e0137065","DOI":"10.1371\/journal.pone.0137065","volume":"10","author":"LJ Goodall","year":"2015","unstructured":"Goodall LJ, Ovecka M, Rycroft D, Friel SL, Sanderson A, Mistry P, et al. Pharmacokinetic and pharmacodynamic characterisation of an anti-mouse TNF receptor 1 domain antibody formatted for in vivo half-life extension. PLoS One. 2015;10:e0137065.","journal-title":"PLoS One"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08911-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08911-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T19:02:39Z","timestamp":1780167759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08911-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8911"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08911-x","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of W\u00fcrzburg has filed a patent application for the use of anti-CD40 antibody fusion proteins with intrinsic agonistic activity with IL, DS, AB and HW as co-inventors. Oligovalent nanobody-based TNFR agonists beyond CD40 have been disclosed to the TTO of the University of W\u00fcrzburg; the decision is pending. AB and HW are cofounders of TrimmunoTec GmbH, which develops bi- and oligospecific conditional TNFR agonists.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experimental procedures were conducted in accordance with relevant institutional guidelines and regulations. Leukocyte reduction system (LRS) chambers from anonymous donors for PBMC isolation were obtained from the Institute of Clinical Transfusion Medicine and Hemotherapy of the University Hospital W\u00fcrzburg. The sex of the donors was not available to us. No human participants or live animals were used in this study, and no identifiable human data or images were collected or used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"518"}}